Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Autor: Maju Mathew Koola, Heidi J. Wehring, Sheryl Thedford, Deanna L. Kelly

Publikováno v: Journal of Central Nervous System Disease
Journal of Central Nervous System Disease, Vol 2011, Iss 3, Pp 107-123 (2011)
Journal of Central Nervous System Disease, Vol 3 (2011)

Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f32c1846da165dda968df79852720a
http://europepmc.org/articles/PMC3535454